


## Data Sheet

<b>Product Name:</b>	WAY-100635 Maleate
<b>Cat. No.:</b>	CS-0019684
<b>CAS No.:</b>	1092679-51-0
<b>Molecular Formula:</b>	C29H38N4O6
<b>Molecular Weight:</b>	538.64
<b>Target:</b>	5-HT Receptor; Dopamine Receptor
<b>Pathway:</b>	GPCR/G Protein; Neuronal Signaling
<b>Solubility:</b>	H <sub>2</sub> O : 25 mg/mL (46.41 mM; Need ultrasonic); DMSO : ≥ 250 mg/mL (464.13 mM)



### BIOLOGICAL ACTIVITY:

WAY-100635 maleate is a potent and selective **5-hydroxytryptamine 1A (5-HT<sub>1A</sub>) receptor** antagonist with an IC<sub>50</sub> value of 0.91 nM and K<sub>i</sub> value of 0.39 nM. WAY-100635 maleate has pIC<sub>50</sub> values for **5-HT<sub>1A</sub>** and α<sub>1</sub>-adrenergic receptors of 8.9 and 6.6, respectively. WAY-100635 maleate is also a potent **dopamine D<sub>4</sub> receptor** agonist<sup>[1][2][3]</sup>. IC<sub>50</sub> & Target: pIC<sub>50</sub> Value: 8.87 (5-HT<sub>1A</sub> Receptor)<sup>[1]</sup>. **In Vitro:** The functional properties and binding affinities of WAY-100635 are evaluated in HEK 293 cells stably expressing dopamine D<sub>2L</sub> or D<sub>4.4</sub> receptors<sup>[1]</sup>.

WAY-100635 displays 940, 370, and 16 nM binding affinities at D<sub>2L</sub>, D<sub>3</sub>, and D<sub>4.2</sub> receptors, respectively. Saturation analyses demonstrate that the K<sub>d</sub> of [<sup>3</sup>H] WAY-100635 at D<sub>4.2</sub> receptors is 2.4 nM. WAY-100635 is potent agonist in HEK-D<sub>4.4</sub> cells with EC<sub>50</sub> of 9.7 nM. WAY-100635 possesses high affinity for D<sub>4.4</sub> receptor (3.3 nM) <sup>[1]</sup>. **In Vivo:** WAY-100635 (1 mg/kg; subcutaneous injection; male Sprague-Dawley rats) treatment abolishes the reduction of the severity of abstinence signs induced by Rhodiola rosea administration in nicotine-dependent rat<sup>[2]</sup>.

### References:

- [1]. Chemel BR, et al. WAY-100635 is a potent dopamine D4 receptor agonist. Psychopharmacology (Berl). 2006 Oct;188(2):244-51.
- [2]. Mannucci C, et al. Serotonin involvement in Rhodiola rosea attenuation of nicotine withdrawal signs in rats. Phytomedicine. 2012 Sep 15;19(12):1117-24.
- [3]. Al Hussainy R, et al. Design, synthesis, radiolabeling, and in vitro and in vivo evaluation of bridgehead iodinated analogues of N-<2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl>-N-(pyridin-2-yl)cyclohexanecarboxamide (WAY-100635) as potential SPECT ligands for the 5-HT<sub>1A</sub> receptor. J Med Chem. 2011 May 26;54(10):3480-91.

### CAIndexNames:

Cyclohexanecarboxamide, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinyl-, (2Z)-2-butenedioate (1:1)

### SMILES:

O=C(O)/C=C\C(O)=O.O=C(N(C1=NC=CC=C1)CCN2CCN(CC2)C3=CC=CC=C3OC)C4CCCCC4.[1:1]

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 732-484-9848 Fax: 888-484-5008 E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA